Progyny Analyst Ratings
KeyBanc Maintains Progyny(PGNY.US) With Hold Rating
Truist Financial Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $26
Progyny (PGNY) Receives a Buy From Truist Financial
J.P. Morgan Maintains Progyny(PGNY.US) With Buy Rating
Maintaining Market Edge: Progyny's Buy Rating Despite Competitive Pressures
Progyny Is Maintained at Hold by Canaccord Genuity
Progyny Analyst Ratings
BofA Securities Maintains Progyny(PGNY.US) With Buy Rating, Announces Target Price $22
Jefferies Maintains Progyny(PGNY.US) With Buy Rating, Cuts Target Price to $24
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $25 to $30
Progyny Price Target Cut to $24.00/Share From $31.00 by Jefferies
Progyny Is Maintained at Market Perform by Leerink Partners
Progyny Stock Sinks 25% After Losing a Big Client. Why This Analyst Still Likes the Stock. -- Barrons.com
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $25 to $30
Analysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Progyny (PGNY)
Progyny's Buy Rating Affirmed: Strategic Growth Potential Outweighs Setbacks
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY) and Roivant Sciences (ROIV)
Progyny Cut to Market Perform From Market Outperform by JMP Securities
Progyny Analyst Ratings